Abstract
Stroke and other thromboembolic events in the brain are often due to carotid artery atherosclerosis, and atherosclerotic plaques with inflammation are considered particularly vulnerable with an increased risk of becoming symptomatic. At present, however, patients are selected for carotid surgical intervention on the basis of the degree of stenosis alone, and not the vulnerability or inflammation of the lesion. During the past decade, research, using PET with the glucose analog tracer 18F-fluor-deoxy-glucose, has been implemented for identifying increased tracer uptake in symptomatic carotid plaques, and tracer uptake has been shown to correlate with plaque inflammation and vulnerability. These findings imply that FDG-PET might hold the promise for a new and better diagnostic test to identify patients eligible for carotid endarterectomy. The rationale for developing diagnostic tests based on molecular imaging with FDG-PET, as well as methods for simple clinical PET approaches, are discussed.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Imaging in Medicine |
Vol/bind | 3 |
Udgave nummer | 1 |
Sider (fra-til) | 17-30 |
Antal sider | 14 |
ISSN | 1755-5191 |
Status | Udgivet - feb. 2011 |